Neuro-Oncology Reviews
Volume
28 Number 1
10 January 2026
Home > Publications > Neuro-Oncology Reviews > Volume 28, Year 2026 > Number 1, 10 January
Vrachas D, Kosma E, Giannopoulou AI, Margoni A, Gargalionis AN,
El-Habr EA, Piperi C, Adamopoulos C.
Targeting
the MAPK Pathway in Brain Tumors: Mechanisms and Therapeutic
Opportunities.
Cancers
(Basel). 2026 Jan 2;18(1):156. doi:
10.3390/cancers18010156. PMID:
41514664. Review. ˍ
Gómez EG, Morales MAM, San-Juan D, Romero-Valencia J,
Mendez DLR, Hernandez DOL, Pizarro MM, Narvaez ERB, Pelayo-Salazar
ME, Jimenez SM.
Efficacy and safety of
immune checkpoint inhibitors and mTOR inhibitors as targeted
therapy for glioblastoma: A systematic review and meta-analysis of
randomized clinical trials.
Neurosurg
Rev. 2026 Jan 3;49(1):95. doi:
10.1007/s10143-025-04043-6. PMID:
41484472. Review; Meta-analysis˰
ˍ
Sanikommu S, Santos AN, Wipplinger C, Dawoud B, Komotar RJ, Lu VM.
Patient-reported outcomes as
prognostic indicators for overall survival and progression-free
survival in brain tumor patients - a systematic review and
meta-analysis of randomized clinical trials.
J
Neurooncol. 2026 Jan 5;176(2):154. doi:
10.1007/s11060-025-05419-w. PMID:
41491296. Review; Meta-analysis.
ˍ
Goh LSH, Thng DKH, Ang YLE, Ho D, Toh TB, Wong ALA.
The
functional imperative in high-grade glioma.
Exp
Mol Med. 2026 Jan 8. doi:
10.1038/s12276-025-01614-x. PMID:
41501375. Review. ˍ
Moreno-Sanchez PM, Rezaeipour M, Inderberg EM, Platten M,
Golebiewska A.
Immunosuppressive
mechanisms and therapeutic interventions shaping glioblastoma
immunity.
Nat
Cancer. 2026 Jan 8. doi:
10.1038/s43018-025-01097-9. PMID:
41507535. Review˰
ˍ
Harper SD, Alderete JA, Baisiwala S, Bergsneider BH, Liau LM, Wang
AC.
Vaccine therapy for pediatric
high-grade glioma: current landscape, challenges, and future
directions.
J
Neurooncol. 2026 Jan 8;176(2):158. doi:
10.1007/s11060-025-05403-4. PMID:
41504830. Review. ˍ
Fortunato JT, Scharf A, Shuman AG, Diamond EL.
Staging
prognostic discussions about glioblastoma.
J
Neurooncol. 2026 Jan 9;176(2):162. doi:
10.1007/s11060-025-05356-8. PMID:
41511573. Review. ˍ
Khizar M, Zaib M, Mahato RK.
Nanorobots
crossing the blood-brain barrier for targeted chemotherapy: the
next frontier.
Ann
Med Surg (Lond). 2025 Dec 6;88(1):1124-1125. doi:
10.1097/MS9.0000000000004532. PMID:
41496916. Perspective. ˍ
Wang B, Li C, Gu J, Wang X, Xun M, Jiang B, Yan J.
Targeting
glioma-associated microglia and macrophages: a new frontier in
glioblastoma immunotherapy.
Front
Immunol. 2025 Dec 17;16:1726440. doi:
10.3389/fimmu.2025.1726440. PMID:
41479886. Review. ˍ
Eibl RH, Schneemann M.
Circulating
Tumor Cells in Glioblastoma.
Cancers
(Basel). 2025 Dec 19;18(1):10. doi:
10.3390/cancers18010010. PMID:
41514523. Review. ˍ
Raja M, Quintero G, Lone YC, Trojan J.
Impact
of Nanotechnology on Glioblastoma Studies: From Brain Stem Cells
to Neoplastic Development and Cancer Gene Therapy.
Front
Biosci (Elite Ed). 2025 Dec 19;17(4):38600. doi:
10.31083/FBE38600. PMID:
41504090. Review. ˍ
Al Sharie S, Sawaftah K, Qasim H, Al-Hussaini M.
Methylation
profiling in neuropathological tumors diagnosis: a comprehensive
review.
Front
Oncol. 2025 Dec 19;15:1720458. doi:
10.3389/fonc.2025.1720458.
PMID:
41487568. Review. ˍ
Russano F, Sturlese M, Dall'Olmo L, Callegarin F, Brugnolo D, Del
Fiore P, Patti V, Purpura A, Moro S, Rastrelli M, Mocellin S.
MDM2 in Tumor Biology and Cancer
Therapy: A Review of Current Clinical Trials.
Int
J Mol Sci. 2025 Dec 22;27(1):99. doi:
10.3390/ijms27010099. PMID:
41515979. Review. ˍ
Spiró Z, El-Heliebi A, Mair MJ, Pieber TR, Prietl B,
Spiegl-Kreinecker S, Stanzer S, Wöhrer A, Preusser M,
Berghoff AS.
Ex vivo drug screening on
patient-derived tumor material to advance functional precision in
oncology: an overview on current approaches and unresolved
challenges.
Cancer
Treat Rev. 2025 Dec 22;143:103072. doi:
10.1016/j.ctrv.2025.103072. PMID:
41475298. Review. ˍ
Agosti E, Panciani PP, Lombardi G, Preusser M, Rosa G, Mapelli K,
Piazza A, Tognetto D, Gagliano C, Denaro L, Padovan M, Fontanella
MM, Zeppieri M, Ius T.
Targeted
therapies in optic pathway gliomas.
Cancer
Treat Rev. 2025 Dec 27;143:103073. doi:
10.1016/j.ctrv.2025.103073. PMID:
41478004. Review. ˍ
Yaacov A, Gillis R, Salim J, Katz D, Asna N, Paldor I, Grinshpun
A.
The Temozolomide Mutational
Signature: Mechanisms, Clinical Implications, and Therapeutic
Opportunities in Primary Brain Tumor Management.
Cells.
2025 Dec 29;15(1):57. doi:
10.3390/cells15010057. PMID:
41511341. Review. ˍ
Deng K, Huang J, Li D, Gao W, Wu M, Lei M.
Application
Value and Research Frontiers of Immunotherapy in Glioblastoma: A
Bibliometric and Visualized Analysis.
Oncol
Res. 2025 Dec 30;34(1):20. doi:
10.32604/or.2025.069442. PMID:
41502522. Bibliometric analysis. ˍ
Dubiński P, Odzimek-Rajska M, Podlewski S, Brola W.
Emerging
Insights into the Role of the Microbiome in Brain Gliomas: A
Systematic Review of Recent Evidence.
Int
J Mol Sci. 2025 Dec 31;27(1):444. doi:
10.3390/ijms27010444. PMID:
41516317. Review. ˍ
Wu AC, Nakamura Y, Kiyotani K.
Advances
in Neoantigen-Based Cancer Vaccines.
Cancers
(Basel). 2025 Dec 31;18(1):144. doi:
10.3390/cancers18010144. PMID:
41514653. Review. ˍ
Cai L, Sun X, Li R, Ping Y, Lv S, Chen J.
Key
methylation modifications in glioma stem cells.
Biochim
Biophys Acta Rev Cancer. 2025 Dec 31;1881(1):189527.
doi:
10.1016/j.bbcan.2025.189527. PMID:
41482238. Review˰ ˍ